Abstract
Recurrent HCV is universal after liver transplantation in patients viremic at the time of transplantation and leads to cirrhosis in up to 30% of patients by five years. Once cirrhosis develops, the risk of hepatic decompensation is 42% per year. This has led to recurrent HCV emerging as an important yet controversial indication for liver retransplantation and a renewed interest in the role of anti-viral therapies. Despite encouraging results with pegylated interferon and ribavirin in the non-transplant HCV population, these findings have not translated to transplant recipients where viral eradication is frequently unsuccessful for genotype 1 patients (
Original language | English (US) |
---|---|
Pages (from-to) | 34-40 |
Number of pages | 7 |
Journal | Anti-Infective Agents |
Volume | 10 |
Issue number | 1 |
DOIs | |
State | Published - Jan 1 2012 |
Externally published | Yes |
All Science Journal Classification (ASJC) codes
- Pharmacology
- Infectious Diseases